Wide Ranks

ACET

Adicet Bio, Inc.

1.11

Top Statistics
Market Cap 91 M Forward PE -0.8510 Revenue Growth 0.00 %
Current Ratio 12.75 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.8050 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 224 M Total Cash Per Share 2.72 Total Debt 19 M
Total Debt To Equity 8.14 Current Ratio 12.75 Book Value Per Share 3.93
All Measures
Short Ratio 704.00 % Message Board Id finmb_310073311 Shares Short Prior Month 4 M
Return On Equity -0.5791 City Boston Uuid 65920c5d-73a6-39e2-8917-c1ab3dd20f9e
Previous Close 0.9603 First Trade Date Epoch Utc 1 B Book Value 3.93
Beta 1.70 Total Debt 19 M Volume 1 M
Price To Book 0.2822 Last Split Date 1 B Fifty Two Week Low 0.8860
Total Cash Per Share 2.72 Shares Short Previous Month Date 1 B Target Median Price 7.00
Audit Risk 8 Max Age 86400 Recommendation Mean 1.57
Sand P52 Week Change 0.3133 Target Mean Price 6.40 Net Income To Common -137291008
Short Percent Of Float 0.0493 Implied Shares Outstanding 82 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 224 M Next Fiscal Year End 1 B Held Percent Insiders 0.0159
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 0.9603 Target Low Price 4.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.31 Open 0.9900
Free Cashflow -55261000 State MA Dividend Yield 0.00 %
Return On Assets -0.2930 Time Zone Short Name EST Board Risk 8
Trailing Eps -1.70 Day Low 0.9601 Address1 131 Dartmouth Street
Shares Outstanding 82 M Compensation Risk 10 Price Hint 4
Target High Price 8.00 Website https://www.adicetbio.com 52 Week Change -0.0593
Average Volume 548235 Forward Eps -1.33 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 1251.50 % Last Split Factor 1:7
Regular Market Day High 1.12 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 8.14 Fifty Two Week High 3.77 Day High 1.12
Shares Short 3 M Regular Market Open 0.9900 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0416
Operating Cashflow -90995000 Currency USD Time Zone Full Name America/New_York
Market Cap 91 M Is_nasdaq_100 False Zip 02116
Quote Type EQUITY Industry Biotechnology Long Name Adicet Bio, Inc.
Overall Risk 10 Regular Market Day Low 0.9601 Held Percent Institutions 0.7644
Current Price 1.11 Address2 3rd Floor Enterprise To Ebitda 0.8050
Financial Currency USD Current Ratio 12.75 Industry Disp Biotechnology
Number Of Analyst Opinions 5 Country United States Float Shares 62 M
Two Hundred Day Average 1.61 Governance Epoch Date 1 B Enterprise Value -97815752
Forward PE -0.8510 Regular Market Volume 1 M Ebitda -121497000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients.

Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.

The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications.

The company was founded in 2014 and is based in Boston, Massachusetts.